Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients

Two-Drug Antiretroviral Regimens expert panel

Research output: Contribution to journalArticle

Abstract

New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in naïve patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both naïve and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.

Original languageEnglish
Pages (from-to)69-80
Number of pages12
JournalThe new microbiologica
Volume42
Issue number2
Publication statusPublished - Apr 1 2019

Fingerprint

HIV-1
HIV
Pharmaceutical Preparations
Guidelines
Costs and Cost Analysis
Therapeutics
Clinical Studies

Keywords

  • Antiretroviral therapy
  • Dolutegravir
  • HIV
  • HIV drug-resistance
  • Two-drug regimens
  • Virological efficacy

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. / Two-Drug Antiretroviral Regimens expert panel.

In: The new microbiologica, Vol. 42, No. 2, 01.04.2019, p. 69-80.

Research output: Contribution to journalArticle

@article{3482c62682664bdab62cc3ab70037de2,
title = "Italian expert panel consensus statements on two-drug antiretroviral regimens to treat na{\"i}ve and virologically suppressed HIV-1 infected patients",
abstract = "New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in na{\"i}ve patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both na{\"i}ve and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.",
keywords = "Antiretroviral therapy, Dolutegravir, HIV, HIV drug-resistance, Two-drug regimens, Virological efficacy",
author = "Andrea Antinori and Santoro, {Maria Mercedes} and Roberta Gagliardini and Giulia Marchetti and Annalisa Mondi and Valeria Cento and Perno, {Carlo Federico} and Massimo Andreoni and {Two-Drug Antiretroviral Regimens expert panel}",
year = "2019",
month = "4",
day = "1",
language = "English",
volume = "42",
pages = "69--80",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "2",

}

TY - JOUR

T1 - Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients

AU - Antinori, Andrea

AU - Santoro, Maria Mercedes

AU - Gagliardini, Roberta

AU - Marchetti, Giulia

AU - Mondi, Annalisa

AU - Cento, Valeria

AU - Perno, Carlo Federico

AU - Andreoni, Massimo

AU - Two-Drug Antiretroviral Regimens expert panel

PY - 2019/4/1

Y1 - 2019/4/1

N2 - New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in naïve patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both naïve and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.

AB - New strategies for HIV treatment able to reduce drug-exposure, medium-long term toxicities and costs are a recognized clinical need. The availability of newer drugs with improved potency and tolerability, as well as high genetic barrier to resistance, makes antiretroviral-sparing strategies with two-drug regimens (2DRs) particularly attractive. Substantial evidence has been generated over the last few years supporting 2DR in virologically suppressed HIV infected patients for whom a therapy switch is planned. More recently, very promising data on 2DR in naïve patients have also been reported. The main purpose of this consensus is to provide an overview of guideline indications and recommendations, and the most recent data from clinical studies of 2DR in both naïve and virologically suppressed patients. As an expert consensus, suggestions and indications on the use and management of 2DR are also provided.

KW - Antiretroviral therapy

KW - Dolutegravir

KW - HIV

KW - HIV drug-resistance

KW - Two-drug regimens

KW - Virological efficacy

UR - http://www.scopus.com/inward/record.url?scp=85067184269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067184269&partnerID=8YFLogxK

M3 - Article

C2 - 30785209

AN - SCOPUS:85067184269

VL - 42

SP - 69

EP - 80

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 2

ER -